Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque

PHASE4CompletedINTERVENTIONAL
Enrollment

1,608

Participants

Timeline

Start Date

October 5, 2015

Primary Completion Date

October 19, 2023

Study Completion Date

October 19, 2023

Conditions
Coronary Artery DiseasePlaque, Atherosclerotic
Interventions
DEVICE

Coronary intervention

bioabsorbable vascular scaffolds (BVS) (early period) or everolimus-eluting stents (middle and late period) + Optimal Medical Treatment

DRUG

Optimal Medical treatment

Trial Locations (18)

Unknown

Columbia University Medical Center, New York

Kyoto University Hospital, Kyoto

Christchurch Hospital and Canterbury DHB, University of Otago, Christchurch

Hallym University Sacred Heart Hospital, Anyang

Gangwon National Univ. Hospital, Chuncheon

Keimyung University Dongsan Medical Center, Daegu

Chungnam National University Hospital, Daejeon

The Catholic University of Korea, Daejeon ST. Mary's Hospital, Daejeon

Chonnam National University Hospital, Gwangju

Gachon University Gil Hospital, Incheon

ChonBuk National University Hospital, Jeonju

Samsung Medical Center, Seoul

Seoul National University hospital, Seoul

The Catholic University of Korea Seoul St. Mary's Hospital, Seoul

Bundang Cha Medical Center, Sŏngnam

Seoul National University Bundang hospital, Sŏngnam

National Taiwan University Hospital, Taipei

138-736

Asan Medical Center, Seoul

All Listed Sponsors
collaborator

CardioVascular Research Foundation, Korea

OTHER

lead

Seung-Jung Park

OTHER

NCT02316886 - Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque | Biotech Hunter | Biotech Hunter